WASHINGTON, July 1, 2019 /PRNewswire/ -- The
Antimicrobials Working Group (AWG) announced today the addition of
X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of
companies with the mission to combat drug resistant infections and
spur life-saving innovations. This new addition brings AWG's
membership to 14 antimicrobial drug companies.
X-Biotix is focused on the discovery of novel small molecule
antibiotics that target resistant Gram-negative bacteria. The
company employs a unique combination of proprietary biological and
genetic tools, library screening, and its deep knowledge of
antibacterial medicinal chemistry to discover and advance novel
tractable chemical matter into optimized
antibacterial molecules that show selective activity
against all or specific gram-negative ESKAPE pathogens and
which can be further developed into drug candidates. Priority is
given to the screening of multiple targets that have the
potential to be inhibited by one compound (dual target
"X-Biotix's pipeline of novel small-molecule antibiotics
directed against multi-drug resistant (MDR) gram-negative pathogens
is being developed to address the urgent threat of antimicrobial
resistance," said Evan Loh, M.D.,
Chief Executive Officer of Paratek Pharmaceuticals and Chairman of
the AWG. "We are glad to have X-Biotix join our efforts to
stabilize the antimicrobial ecosystem and support innovation in the
development of new infection-fighting drugs."
"Since its inception, the Antimicrobials Working Group has done
a tremendous job of charting a path for improving the regulatory,
investment and commercial environment for the development of
antimicrobial drugs," said Ramani
Varanasi, President and Chief Executive Officer of X-Biotix
Therapeutics. "We are pleased to be joining this coalition at this
critical time and to be participating in the coordinated efforts to
effectuate policy changes that will enable the effective delivery
of much-needed antimicrobials to patients in need."
All pharmaceutical and biotechnology companies developing new
antimicrobial therapeutics and diagnostic devices are eligible for
consideration of membership in AWG. If you are interested in
learning more about becoming a member of AWG, please contact
About X-Biotix Therapeutics, Inc.
X-Biotix is a discovery and development company, with a focus on
delivering the next generation of antibiotics to combat multi-drug
resistant Gram-negative pathogens. The company, incorporated in
2016 and located in Waltham, MA.,
is advancing multiple first-in-class small molecule compounds,
identified using a unique DNA-encoded library platform, against a
wide range of bacterial targets in essential pathways, which are
predicted to defeat known antibiotics resistance mechanisms.
For more information, visit: http://www.x-biotixrx.com/
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of fourteen antimicrobials companies: Amplyx
Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc.
(NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis
Therapeutics Inc. (NASDAQ: ETTX), Iterum Therapeutics Ltd. (NASDAQ:
ITRM), Melinta Therapeutics Inc. (NASDAQ: MLNT), Nabriva
Therapeutics US Inc. (NASDAQ: NBRV), Paratek Pharmaceuticals Inc.
(NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc. (NASDAQ: SCYX),
Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM), VenatoRx
Pharmaceuticals, Inc., and X-Biotix Therapeutics, Inc.
For more information, visit:
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
SOURCE Antimicrobials Working Group (AWG)